Andere Sprachen Zealand Pharma A/S

Aktien

A0YJW7

DK0060257814

ZEAL

Biotechnologie

Markt geschlossen - Nasdaq Copenhagen Andere Börsenplätze 17:20:00 16.12.2025			% 5 Tage	Veränd. 1. Jan.
469,60 ^DKK	-3,43 %		-7,19 %	-34,37 %

16.12.	Die Deutsche Bank erhöht das Kursziel für Zealand Pharma auf 450 DKK (430) und bekräftigt die Empfehlung „Halten“	FW
15.12.	Zealand Pharma A/S - Analyst/Investor Day

Andere Sprachen

Weight-loss drug developers line up to tap lucrative market as competition heats up	12.12.
Mips, LPP et Wendel brillent, Eutelsat et Elior font machine arrière	12.12.
Zealand Pharma A/S : Capital Markets Day 2025	12.12.
Zealand Pharma increases its share capital as a result of the exercise of employee warrants	11.12.
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration	11.12.
OTR Therapeutics and Zealand Pharma A/S Enter Multi- Program Strategic Collaboration and License Agreement to Develop Novel Therapies for Metabolic Diseases	11.12.
Zealand Pharma, OTR Therapeutics enter strategic collaboration	11.12.
Zealand Pharma seeks to challenge GLP-1 dominance with obesity drug aimed at long-term use	11.12.
Zealand Pharma outlines Metabolic Frontier 2030 strategy	11.12.
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health	11.12.
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases	11.12.
Weight-loss drug developers line up to tap lucrative market as competition heats up	08.12.
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons	05.12.
REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025	01.12.
Weight-loss drug developers line up to tap lucrative market as competition heats up	25.11.
Zealand Pharma A/S : Interim Report Q3 2025	14.11.
Zealand Pharma A/S : Interim Report for Q3 2025	14.11.
Zealand Pharma suspends obesity project to focus on programs with greater potential	13.11.
Zealand Pharma suspend un projet contre l'obésité pour se concentrer sur des programmes à plus fort potentiel	13.11.
Zealand Pharma pauses development of early-stage obesity drug candidate	13.11.
ALK respire, Eckert s'illumine… mais Siemens perd du courant	13.11.
Zealand Pharma scraps obesity drug candidate, citing crowded market, Bloomberg News reports	13.11.
Zealand scraps potential obesity drug, citing crowded market - Bloomberg News	13.11.
U.S. Futures, European Stocks Up	13.11.
Zealand Pharma Q3 operating loss DKK 461.3 million	13.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Zealand Pharma: Jackpot mit Roche

Am 12. März 2025 um 15:53 Uhr